Apalutamide Regimen Cuts Metastasis Risk in High-Risk Prostate Cancer

Trial Evaluates Perioperative Apalutamide With Surgery

Adding apalutamide and hormone therapy around surgery reduced the risk of metastasis or death by 51 percent in patients with high-risk localized prostate cancer. The finding comes from a Phase 3 randomized substudy presented at the European Society for Medical Oncology (ESMO) Congress 2026 and published in European Urology.

Investigators tested whether six months of systemic treatment before and after surgery improved outcomes over standard radical prostatectomy alone. Apalutamide functions as an androgen-receptor pathway inhibitor (ARPI), blocking male hormones that drive prostate cancer growth.

Substudy Compares Combination Therapy to Radical Prostatectomy Alone

The PROTEUS substudy enrolled 408 participants diagnosed with high-risk localized or locally advanced prostate cancer across a 1:3 randomized design. Patients in the intervention arm received apalutamide alongside androgen-deprivation therapy (ADT) for six months prior to and six months following radical prostatectomy with pelvic lymph-node dissection.

The control group underwent standard radical prostatectomy alone without perioperative medication. Researchers followed participants for a median duration of 37.8 months to track relapse and survival outcomes.

• Event-free survival improved by 62 percent, tracking prostate-specific antigen (PSA) levels, conventional imaging, and PSMA-PET scans.
• Risk of metastasis or death dropped by 51 percent compared with prostatectomy alone.
• Risk of starting a subsequent cancer therapy fell by 71 percent.
• Fifty percent fewer patients required secondary cancer therapy by year three.

How the New Data Builds on Earlier Findings

Earlier data from the main PROTEUS trial evaluated the regimen against hormone therapy alone rather than surgery alone. Those results, published in The New England Journal of Medicine, showed patients were nine times more likely to show minimal or absent tumor tissue at resection.

That initial comparison also demonstrated a 20 percent reduction in metastatic progression or death and extended time to subsequent therapy by 33 months. The newer substudy answers how the combined drug regimen performs against surgery alone, which remains a standard surgical pathway.

Hormone Suppression Context for Metabolic Health

Androgen-receptor inhibition directly affects systemic hormone balance by suppressing testosterone signaling. Prostate cells depend on androgen stimulation to multiply, which makes receptor blockade an effective oncologic target.

Systemic androgen suppression also influences broader physiology, including lean muscle mass, glucose regulation, and lipid metabolism. Patients evaluating extended hormone regimens often review these metabolic shifts with their care teams during prolonged suppression cycles.

Current Regulatory Status and Clinical Caveats

Apalutamide currently holds regulatory approval for metastatic castration-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer, but not yet as a standard perioperative treatment for localized disease. Use before and after surgery remains investigational while regulatory agencies evaluate the full trial data.

Reported side effects remained consistent with earlier apalutamide safety profiles. Individuals with localized prostate cancer can discuss clinical trial data and surgical options with their oncologist to understand whether systemic perioperative therapy fits their clinical profile.